About HATIP

A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.

Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.

Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.

latest aidsmap news

• Updated British HIV pregnancy guidelines published
• Incidence increasing of HIV-associated multicentric Castleman's disease, a relatively rare lymphatic cancer
• Rapid progression of liver fibrosis in HIV-positive gay men recently infected with hepatitis C
• Low CD4 cell count, but not HIV treatment, increases risk of hardening of the arteries
• Long-term HIV treatment cuts risk of hardening of coronary artery
• Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks
• Will male circumcision protect women, ask advocates?
• Do not use HIV tests bought over the internet, warns UK medicines regulators
• `Express care` by nurses for people starting HIV treatment decreases clinic congestion, and may improve outcomes
• Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year